Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NK-520
- Development stage
- Phase 1
- Lead developer
- Base Therapeutics
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Silencing → Gene Therapies, Covalent Small Molecules → Small Molecules, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies
- Administration
- Intravenous
01
Overview
NK-520 is an investigational natural killer (NK) cell therapy developed by Base Therapeutics for the treatment of hematologic malignancies, primarily acute myeloid leukemia (AML). It is classified as a cell therapy and functions through immunologic cytotoxicity and natural killer cell replacement mechanisms. The drug is administered intravenously and is currently in early clinical development (Early Phase 1/Phase 0) for relapsed or refractory AML in both adult and pediatric populations. There has also been preclinical investigation for ovarian cancer. As of now, there are no approved indications or known adverse events reported for this product.
02
Targets
MICB (Major histocompatibility complex class i-related protein B)
Beyond the preview
Go deeper on NK-520.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NK-520.